|Values are valid only on day of printing.|
Evaluating patients with chronic myeloid leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI), therapy, who are apparently failing treatment
This is the preferred initial test to identify the presence of acquired BCR-ABL mutations associated with TKI-resistance.
If BCR/ABL fusion type (p210, p190, p185 or p230) are not provided, BADX / BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay will be performed at an additional charge.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis Allele-Specific Primer Extension (ASPE) and Detection by Luminex Bead Array
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)